


Meeting Overview

Category	Number
Votable Meetings	36
Meetings Voted	36
Proxy Contests Voted	0
Meetings with Against Management Votes	24
Meetings with Against ISS Votes	5


Comparison of Meetings Voted



With 36 meetings available to vote during the period, 36 were voted, equating to approximately 100% of the votable meetings with close to 0% unvoted.


Alignment with Management

- Comparing vote cast alignment with management recommendations highlights similarities and differences between your governance philosophies and the investee's approach to key corporate governance issues.
- The votes cast on Kieger AG ballots during the reporting period are aligned with management recommendations in 87% of cases, while the ISS Benchmark Policy recommendations are at 88% alignment with management recommendations.




Votes Cast on Management Proposal Categories

- › Comparing the votes cast in support of Management proposals, ISS Benchmark Policy recommendations across the major proposal categories provides insight into the positioning of votes on proposals submitted by Shareholders against the aforementioned benchmarks.
- › Votes cast during the reporting period were least in line with management on Company Articles matters, where only 75% of votes followed management recommendations.
- › Across categories, votes cast on management proposals show the closest alignment to the ISS Benchmark Policy guidelines.



Votes Cast on Shareholder Proposal Categories

- › Comparing the votes cast in support of Shareholder proposals, ISS Benchmark Policy recommendations across the major proposal categories provides insight into the positioning of votes on proposals submitted by Shareholders against the aforementioned benchmarks.
- › Votes cast during the reporting period show the highest level of support for shareholder proposals related to Director Related, Environmental, at 100% and the lowest level of support for shareholder proposals related to Audit Related, Company Articles, Director Election, E&S Blended, with 0% of proposals supported.
- › Across categories, votes cast on shareholder proposals show the closest alignment to the ISS Benchmark Policy guidelines.



Sector	% Meetings Voted	% of Companies with ISS Governance QualityScore of 8, 9 or 10 ¹	% of Votes Cast Against Management	% of Votes Cast Against ISS Benchmark Policy
Communication Services	N/A	N/A	N/A	N/A
Consumer Discretionary	N/A	N/A	N/A	N/A
Consumer Staples	N/A	N/A	N/A	N/A
Energy	N/A	N/A	N/A	N/A
Financials	N/A	N/A	N/A	N/A
Health Care	100%	13%	13%	4%
Industrials	N/A	N/A	N/A	N/A
Information Technology	N/A	N/A	N/A	N/A
Materials	N/A	N/A	N/A	N/A
Real Estate	N/A	N/A	N/A	N/A
Utilities	N/A	N/A	N/A	N/A
TOTALS	100%	13%	13%	4%

Region	% Meetings Voted	% of Companies with ISS Governance QualityScore of 8, 9 or 10 ¹	% of Votes Cast Against Management	% of Votes Cast Against ISS Benchmark Policy
Africa	100%	0%	0%	0%
Americas	100%	10%	10%	7%
Antarctica	N/A	N/A	N/A	N/A
Asia	N/A	N/A	N/A	N/A
Europe	100%	20%	17%	1%
North America	N/A	N/A	N/A	N/A
Oceania	N/A	N/A	N/A	N/A
Unknown	N/A	N/A	N/A	N/A
TOTALS	100%	13%	13%	4%


¹Percentages based on the universe of holdings within the ISS Governance QualityScore coverage universe.

Largest Portfolio Positions with High Governance Risk

The table below highlights the top 15 largest positions for those companies deemed high-risk, as indicated by an ISS Governance QualityScore between 8 and 10. Companies are only shown if they held a meeting during the reporting period.

Company	Ticker	Estimated Position Value (USD) ¹	ISS Governance QualityScore	Board Structure	Compensation/Remuneration	Shareholder Rights & Takeover Defenses	Audit & Risk Oversight
Axsome Therapeutics, Inc.	AXSM	2.6 M	8	8	8	8	7
Amplifon SpA	AMP	1.9 M	10	9	10	9	2
bioMerieux SA	BIM	1.2 M	8	7	9	8	5
LifeStance Health Group, Inc.	LFST	813,363.0	10	10	8	7	10

Portfolio Risk by ISS Governance QualityScore



13%² of the companies within your portfolio that held meetings during the reporting period are high risk, falling within the ISS Governance QualityScore range of **10** through **8**.

ISS Governance QualityScore is a data driven scoring and screening solution designed to identify governance risk within companies. ISS Governance QualityScore is derived from publicly disclosed data on the company's governance practices. Scores indicate decile rank relevant to index or region. For more information on ISS Governance QualityScore, visit <https://www.issgovernance.com/solutions/iss-analytics/qualityscore/>.

¹Estimated values are based on shares held on record date for the company's most recently held meeting during the reporting period. Please contact your ISS Client Service Team with any questions related to how this value is calculated.

²Percentages based on the universe of holdings within the ISS Governance QualityScore coverage universe.

Contested Meetings Overview

There is no applicable content to display for the reporting period.

*Values are based on shares held on record date for the company's meeting held during the reporting period. Please contact your ISS Client Service Team with any questions related to how this value is calculated.

Contested Meetings & Largest Portfolio Positions with High Governance Risk Meeting Details

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
Amplifon SpA	AMP	1908506	23-Apr-2025	1.1	Accept Financial Statements and Statutory Reports	For		For	
Amplifon SpA	AMP	1908506	23-Apr-2025	1.2	Approve Allocation of Income	For		For	
Amplifon SpA	AMP	1908506	23-Apr-2025	2.1	Fix Number of Directors	For		For	
Amplifon SpA	AMP	1908506	23-Apr-2025	2.2.1	Slate 1 Submitted by Ampliter Srl	None		Against	
Amplifon SpA	AMP	1908506	23-Apr-2025	2.2.2	Slate 2 Submitted by Institutional Investors (Assogestioni)	None		For	
Amplifon SpA	AMP	1908506	23-Apr-2025	3	Approve Remuneration of Directors	For		For	
Amplifon SpA	AMP	1908506	23-Apr-2025	4.1	Approve Remuneration Policy	For		Against	
Amplifon SpA	AMP	1908506	23-Apr-2025	4.2	Approve Second Section of the Remuneration Report	For		Against	
Amplifon SpA	AMP	1908506	23-Apr-2025	5	Authorize Share Repurchase Program and Reissuance of Repurchased Shares	For		For	
Amplifon SpA	AMP	1908506	23-Apr-2025	6	Amend Regulations on General Meetings	For		Against	
bioMérieux SA	BIM	1940644	15-May-2025	1	Approve Financial Statements and Statutory Reports	For		For	
bioMérieux SA	BIM	1940644	15-May-2025	2	Approve Consolidated Financial Statements and Statutory Reports	For		For	
bioMérieux SA	BIM	1940644	15-May-2025	3	Approve Discharge of Directors	For		Against	
bioMérieux SA	BIM	1940644	15-May-2025	4	Approve Allocation of Income and Dividends of EUR 0.90 per Share	For		For	
bioMérieux SA	BIM	1940644	15-May-2025	5	Approve Transaction with bioMérieux India Pvt Ltd	For		For	
bioMérieux SA	BIM	1940644	15-May-2025	6	Reelect Marie-Paule Kieny as Director	For		For	
bioMérieux SA	BIM	1940644	15-May-2025	7	Reelect Fanny Letier as Director	For		For	

Reporting Period: 30-Sep-2024 to 30-Sep-2025

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
bioMerieux SA	BIM	1940644	15-May-2025	8	Approve Remuneration Policy of Corporate Officers	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	9	Approve Remuneration Policy of Chairman of the Board	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	10	Approve Remuneration Policy of CEO	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	11	Approve Remuneration Policy of Directors	For		For	
bioMerieux SA	BIM	1940644	15-May-2025	12	Approve Compensation Report of Corporate Officers	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	13	Approve Compensation of Alexandre Merieux, Chairman of the Board	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	14	Approve Compensation of Pierre Boulud, CEO	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	15	Approve Amended Share Purchase Program (MyShare 2025) Reserved for Beneficiaries Employed in the State of California, USA	For		For	
bioMerieux SA	BIM	1940644	15-May-2025	16	Authorize Repurchase of Up to 10 Percent of Issued Share Capital	For		For	
bioMerieux SA	BIM	1940644	15-May-2025	17	Authorize Decrease in Share Capital via Cancellation of Repurchased Shares	For		For	
bioMerieux SA	BIM	1940644	15-May-2025	18	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights (Rights Issue) up to Aggregate Nominal Amount of EUR 4,210,280	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	19	Approve Issuance of Equity or Equity-Linked Securities up to 20 Percent of Issued Capital for Private Placements	For		Against	

Reporting Period: 30-Sep-2024 to 30-Sep-2025

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
bioMerieux SA	BIM	1940644	15-May-2025	20	Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 4,210,280	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	21	Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	22	Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 18, 19, and 20	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	23	Authorize Capital Increase of up to 20 Percent of Issued Capital for Contributions in Kind	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	24	Authorize Capitalization of Reserves of Up to EUR 4,210,280 for Bonus Issue or Increase in Par Value	For		For	
bioMerieux SA	BIM	1940644	15-May-2025	25	Authorize Issuance of Equity Upon Conversion of a Subsidiary's Equity-Linked Securities without Preemptive Rights for Up to EUR 4,210,280	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	26	Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 4,210,280	For		For	
bioMerieux SA	BIM	1940644	15-May-2025	27	Amend Articles of Bylaws	For		Against	
bioMerieux SA	BIM	1940644	15-May-2025	28	Authorize Filing of Required Documents/Other Formalities	For		For	
LifeStance Health Group, Inc.	LFST	1960557	03-Jun-2025	1.1	Elect Director Teresa DeLuca	For		Withhold	

Reporting Period: 30-Sep-2024 to 30-Sep-2025

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
LifeStance Health Group, Inc.	LFST	1960557	03-Jun-2025	1.2	Elect Director Katherine Wood	For		Withhold	
LifeStance Health Group, Inc.	LFST	1960557	03-Jun-2025	1.3	Elect Director Eric Palmer	For		For	
LifeStance Health Group, Inc.	LFST	1960557	03-Jun-2025	2	Ratify PricewaterhouseCoopers LLP as Auditors	For		For	
LifeStance Health Group, Inc.	LFST	1960557	03-Jun-2025	3	Advisory Vote to Ratify Named Executive Officers' Compensation	For		For	
Axsome Therapeutics, Inc.	AXSM	1962990	06-Jun-2025	1	Elect Director Roger Jeffs	For		Withhold	
Axsome Therapeutics, Inc.	AXSM	1962990	06-Jun-2025	2	Approve Omnibus Stock Plan	For		Against	
Axsome Therapeutics, Inc.	AXSM	1962990	06-Jun-2025	3	Ratify Deloitte & Touche LLP as Auditors	For		For	
Axsome Therapeutics, Inc.	AXSM	1962990	06-Jun-2025	4	Advisory Vote to Ratify Named Executive Officers' Compensation	For		For	

PARAMETERS

Location(s): All Locations
Account Group(s): All Account Groups
Institution Account(s): Kieger Impact Healthcare Fund
Custodian Account(s): All Custodian Accounts
ADR Meetings: All Meetings
Client Covered: – None –
Contrary Votes: All Votes
Date Format: DD-MMM-YYYY
ISS Governance QualityScore < =: None
ISS Governance QualityScore > =: None
Highlighted Meetings: Include Contested and High Risk Meeting Details
Industry Sectors: All Sectors
Market Cap (USD) < =: None
Market Cap (USD) > =: None
Markets: All Markets
Meeting ID's: All Meeting ID's
Meeting Types: All Meeting Types
PoA Markets: All Markets
Proposal Proponents: All Proponents
Recommendations: All Recommendations
Record Date Markets: All Markets
Reregistration Meetings: Exclude Reregistration Meetings
Shareblocking Markets: All Markets
Speciality Policy: - None -
Vote Instructions: All Instructions
Voting Policies: None
Zero (0) Share Ballots: Exclude 0 Share Ballots
Account Group Watchlist: None
Account Watchlist: None
Country Watchlist: None
Issuer Watchlist: None
Proposal Code Watchlist: None

This document and all of the information contained in it, including without limitation all text, data, graphs and charts (collectively, the "Information") is the property of Institutional Shareholder Services Inc., its subsidiary, ISS Corporate Services, Inc., or in some cases third party suppliers (collectively "ISS"). The Information may not be reproduced or disseminated in whole or in part without prior written permission of ISS.

Information regarding the holdings and other data specific to the named recipient of this report (the "Recipient"), has been compiled from the records of only the asset manager(s) who use ISS' proxy advisory/voting services and who have authorized ISS to include the Recipient's data in this report. ISS believes this data to be reliable but cannot guarantee its accuracy.

The Information has not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body. None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), or a promotion or recommendation of, any security, financial product or other investment vehicle or any trading strategy, nor a solicitation of a proxy, and ISS does not endorse, approve or otherwise express any opinion regarding any issuer, securities, financial products or instruments or trading strategies.

Issuers mentioned in this product may have purchased self-assessment tools and publications from ISS Corporate Services, Inc. ("ICS"), a wholly owned subsidiary of ISS, or ICS may have provided advisory or analytical services to the issuer. No employee of ICS played a role in the preparation of the content of this product. Any issuer that is mentioned in this document may be a client of ISS or ICS, or may be the parent of, or affiliated with, a client of ISS or ICS. If you are an ISS institutional client, you may inquire about any issuer's use of products and services from ICS by emailing disclosure@issgovernance.com.